Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Saw Palmetto

Serenoa repens (the DHT / BPH question)

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Not FDA-approved; sold as a supplement (approved as a phytomedicine in parts of Europe)

Reference only. Not medical advice.

What can go wrong

Generally well tolerated; mild GI upset and, rarely, decreased libido or ejaculatory changes consistent with anti-androgen action. Case reports link it to bleeding and to liver and pancreatic injury. Because it may affect PSA and androgen metabolism, men should disclose use to clinicians evaluating the prostate.

This is something to take to a clinician. The Atlas can tell you what is known about saw palmetto in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Saw palmetto is a fruit extract proposed to inhibit 5-alpha-reductase, the enzyme converting testosterone to dihydrotestosterone (DHT). It is marketed for prostate symptoms (BPH) and hair loss. Crucially, that is a DHT-lowering mechanism, so its inclusion in 'testosterone booster' products is conceptually backwards. The clinical evidence for BPH is mixed and largely negative in the best trials.

Often sold to 'raise testosterone' while its proposed action is the opposite of that.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Benign prostatic hyperplasia symptoms
  • Androgenetic alopecia (anecdotal)
  • Misleadingly included in T-booster blends

How it is supposed to work

Saw palmetto's fatty acids and phytosterols are proposed to inhibit both isoforms of 5-alpha-reductase and to have anti-inflammatory effects in prostate tissue, reducing DHT-driven prostate growth. This mechanism, if real, lowers a downstream androgen rather than raising testosterone.

Why it is in T-boosters at all

Some marketing reasons that by 'blocking' conversion to DHT, more testosterone stays as testosterone, implying a net 'boost.' Even if 5-alpha-reductase inhibition occurred, total testosterone does not meaningfully rise from this in practice, and DHT is itself the more potent androgen. The framing exploits consumer confusion between testosterone and DHT.

What people get wrong

  • Often saidSaw palmetto raises testosterone

    ActuallyIts proposed mechanism lowers DHT; it is not a testosterone raiser and its presence in T-boosters is backwards.

  • Often saidSaw palmetto reliably treats BPH

    ActuallyThe best randomized trials (STEP, CAMUS) and a 2023 Cochrane review found little to no benefit over placebo; results may depend on the specific extract.

Who profits, and who pushes back

  • Cochrane reviewers

    Pushes backSystematic-review authors

    Serenoa repens, alone, provides little to no benefit for BPH symptoms compared with placebo.

  • Hair-loss and prostate-health channels

    Promotes itNiche but loyal

    Mixed disclosure; some promote specific lipidosterolic extracts for affiliate revenue.

What we do not know

  • Do specific lipidosterolic extracts (e.g., Permixon) outperform the generic products tested in negative US trials?
  • Is there any real benefit for hair loss separate from BPH?

At a glance

Proposed action
Inhibits type 1 and 2 5-alpha-reductase
Marketed for
BPH, hair loss, 'prostate health'
Best BPH RCTs
Largely no benefit over placebo (STEP, CAMUS)
T effect
Not a testosterone raiser

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Saw Palmetto. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • STEP trial (Bent et al., NEJM)2006

    Saw palmetto no better than placebo for BPH symptoms or flow

  • CAMUS trial (Barry et al., JAMA)2011

    Escalating doses of saw palmetto did not reduce lower urinary tract symptoms vs placebo

  • Cochrane review (Serenoa repens for BPH)2023

    Concluded saw palmetto alone provides little to no benefit for BPH symptoms